SAM
TXG icon

Shell Asset Management’s 10x Genomics TXG Stock Holding History

Shell Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,663
Closed -$127K – 1433
2022
Q1 		$127K Hold
1,663
– – ﹤0.01% 1256
2021
Q4 		$248K Buy
1,663
+719
+76% +$110K 0.01% 1151
2021
Q3 		$137K Sell
944
-2,228
-70% -$383K ﹤0.01% 1269
2021
Q2 		$621K Buy
3,172
+2,864
+930% +$518K 0.01% 812
2021
Q1 		$56K Hold
308
– – ﹤0.01% 1380
2020
Q4 		$44K Buy
+308
New +$44.7K ﹤0.01% 1385

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Shell Asset Management's TXG Position: Q2 2022 in Review

Shell Asset Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 1,663 shares — an estimated $127K sold.

Shell Asset Management first reported a position in TXG in Q4 2020 and held it in 6 quarters. The position peaked at $621K in Q2 2021. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.

  • Shell Asset Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
  • Shell Asset Management sold 1,663 10x Genomics shares in Q2 2022, an estimated $127K.
  • Shell Asset Management first reported a position in 10x Genomics in Q4 2020 and held it in 6 quarters.
  • Shell Asset Management's 10x Genomics position peaked at $621K in Q2 2021.
  • 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.

Based on Shell Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.